Survival data in patients with de novo non-HGBL and non-HGBL transformed from an indolent lymphoma. Survival was evaluated from eligibility (A, OS) or from infusion (B, PFS; OS, C). Patients with de novo non-HGBL have a significantly lower OS from eligibility (P = .004) and from infusion (P = .014). NA, non atteint (not reached).